Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sirolimus topical gel PTX-022

A topical gel formulation containing the macrolide sirolimus (rapamycin), with potential anti-proliferative and chemopreventive activities. Upon topical administration of sirolimus topical gel PTX-022, sirolimus migrates into the basal keratinocytes and is internalized by the affected cells. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus-FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) and the mTOR-mediated signaling pathways, which reduces cellular proliferation in mTOR-overexpressing cells. Additionally, by inhibiting mTOR, PTX-022 may inhibit translation of mutant keratin mRNAs and the production of mutant keratins in cells in which mutant keratin genes dysregulate keratinocyte proliferation.
Synonym:QTORIN (TM) PTX-022
QTORIN (TM) rapamycin anhydrous gel
topical sirolimus gel PTX-022
Code name:PTX 022
PTX-022
PTX022
Search NCI's Drug Dictionary